{
    "nctId": "NCT06537674",
    "briefTitle": "Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer",
    "officialTitle": "An Exploratory Clinical Study of the PRO of Pyrotinib Combined With Trastuzumab Subcutaneously Compared Intravenous Administration in the Treatment of HER2-positive Early Breast Cancer",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "HER2+ Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 100,
    "primaryOutcomeMeasure": "EORTC QLQ-C30 scale score",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Women aged \u226518 years and \u226475 years who are newly treated for breast cancer;\n2. Pathological examination confirmed HER2 positive (immunohistochemical staining ICH+++ or ICH++ and FISH positive);\n3. Patients with invasive breast cancer diagnosed histologically plus imaging as early (T1c-3, N0-1, M0) or locally advanced (T2-3, N2, or N3, M0);\n4. ECOG score 0-1;\n5. Plan to undergo the final surgical removal of breast cancer, i.e. breast-conserving surgery or total mastectomy, sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND);\n6. If the major organs function normally, the following criteria are met:\n\n(1) The standard of blood routine examination should meet: ANC \u22651.5\u00d7109/L; PLT \u226590\u00d7109/L; Hb \u226590g/L; (2) Biochemical examination should meet the following criteria: TBIL\u2264 upper limit of normal value (ULN); ALT and AST\u22641.5 times the upper limit of normal (ULN); Alkaline phosphatase \u22642.5 times the upper limit of normal (ULN); BUN and Cr\u22641.5\u00d7ULN and creatinine clearance \u226550 mL/min (Cockcroft-Gault formula); (3) Color Doppler ultrasonography and echocardiography: left ventricular ejection fraction (LVEF\u226555%); (4) Fridericia calibrated QT interval (QTcF) for 18-lead ECG \\<470 ms; 7. For female patients who are not menopausal or have not been surgically sterilized, they should consent to abstinence or use an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment.\n\n8. Volunteer to join the study and sign the informed consent.\n\nExclusion Criteria:\n\n1. Known allergic history of the drug components of this protocol;\n2. Previously received antitumor therapy or radiation therapy for any malignant tumor (except for cured cervical carcinoma in situ and basal cell carcinoma);\n3. Has undergone major non-breast cancer related surgery within 4 weeks, or has not fully recovered from such surgery;\n4. Stage IV (metastatic) breast cancer patients;\n5. Inability to swallow, intestinal obstruction, or other factors affecting the administration and absorption of the drug;\n6. Serious heart disease or discomfort that cannot be treated;\n7. Suffering from mental illness or psychotropic substance abuse, unable to cooperate;\n8. Pregnant or lactating women;\n9. Patients with severe liver and kidney function diseases and blood system diseases;\n10. Those who were not considered suitable for inclusion by the researchers included: history of drug abuse, history of use of blood products, anticoagulant drugs and immunological drugs within the past year; Poor compliance and refusal to cooperate with treatment",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}